|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||||||
  Clinical and Experimental Pharmacology and PhysiologyVolume 12 Issue 6, Pages 565 - 571 Published Online: 28 Jun 2007 Journal compilation © 2010 Blackwell Publishing Asia Pty Ltd
Abstract | References | Full Text: PDF (Size: 432K) | Related Articles | Citation Tracking  METOCLOPRAMIDE ENHANCES BETHANECHOL-INDUCED PANCREATIC EXOCRINE SECRETION OF THE DOG Copyright 1985 Blackwell Publishing Asia Pty Ltd KEYWORDS bethanechol, • dog pancreas, • dopamine, • exocrine secretion, • metoclopramide, • sulpiride. ABSTRACT
1. The effects of metoclopramide on pancreatic exocrine secretion were investigated in the pentobarbitone-anaesthetized dog. All drugs were injected into the femoral vein. 2. Metoclopramide (10–1000 μg/kg) did not change the resting rate of pancreatic secretion. 3. Pancreatic secretion, induced by bethanechol (3 μg/kg), was dose-dependently enhanced by simultaneous injections of metoclopramide (10 and 30 μg/kg), but the protein and bicarbonate concentrations of the pancreatic juice were not affected. Secretions induced by secretin (0.1 units/kg) and dopamine (3 μg/kg) were not modified by metoclopramide at up to 30 μg/kg. 4. A larger dose of metoclopramide (1000 μg/kg) suppressed dopamine-induced secretion to a lesser extent than the same dose of sulpiride. 5. From these results, it is concluded that metoclopramide enhances secretory responses to cholinergic stimulations by peripherally sensitizing the muscarinic receptor-mediated exocrine process and this drug is a weaker antagonist of the dopamine D Received 3 January 1985; revision received 22 March 1985 | 
|
